Investor's Business Daily on MSN12h
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback